Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers

The objective of this study was to compare the efficacy of biomarkers in assessing the risk of breast cancer recurrence in patients with node-negative or micrometastatic grade II breast cancer. Specifically, we compared risk assessments based on the St. Gallen clinicopathological criteria, Ki67 expr...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2017-09, Vol.17 (1), p.662-10, Article 662
Main Authors: Deluche, Elise, Venat-Bouvet, Laurence, Leobon, Sophie, Fermeaux, Veronique, Mollard, Joelle, Saidi, Nadira, Jammet, Isabelle, Aubard, Yves, Tubiana-Mathieu, Nicole
Format: Article
Language:English
Subjects:
Adjuvant treatment
Adult
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor - genetics
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cancer
Cancer therapies
Chemotherapy
Chemotherapy, Adjuvant - adverse effects
Comparative analysis
Discordance
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic - drug effects
Grade II
Health aspects
Humans
Ki-67 Antigen - genetics
Ki67
Laboratories
Lymph Nodes - pathology
Lymphatic system
Medical prognosis
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - pathology
Patients
Plasminogen Activator Inhibitor 1 - genetics
Plasminogen activator inhibitors
Prognosis
Risk assessment
Risk Factors
Subtypes
Tumors
U-Plasminogen activator
uPA/PAI-1
Urokinase-Type Plasminogen Activator - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to compare the efficacy of biomarkers in assessing the risk of breast cancer recurrence in patients with node-negative or micrometastatic grade II breast cancer. Specifically, we compared risk assessments based on the St. Gallen clinicopathological criteria, Ki67 expression and urokinase plasminogen activator (uPA)/plasminogen activator inhibitor-1 (PAI-1) expression. This retrospective study included 347 patients with breast cancer followed at Limoges University Hospital. The optimal cut-off for high Ki67 expression (Ki67 ) was established as 20%. The threshold for uPA and PAI-1 positivity was 3 ng/mg and 14 ng/mg, respectively. Ki67 expression was lower in uPA/PAI-1-negative than in uPA/PAI-1-positive tumours (227 tumours; P = 0.04). The addition of Ki67 status to the St. Gallen criteria resulted in a 28% increase in the rate of identification of high-risk tumours with a potential indication for chemotherapy (P 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-017-3648-z